Entrectinib can induce nerve cell damage by inhibiting PI3K-AKT and TGF-β signaling pathways

Authors: Qingshan Tang, Jiachen Dong, Feng Zhang, Dan Zhao, Qi Yang, Jiayu Wen, Yuhao Sun, Jifu Wei, Zhixian Liu

Source: Frontiers in Pharmacology, Vol 16 (2025)

Subject Terms: entrectinib, nerve cell damage, THBS1, Pi3k-akt, TGF-β, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2025.1489210/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/c4e9d8c4763e4f74bdbe9ac0c37bd036

A Novel Oncogenic and Drug-Sensitive KIF5B-NTRK1 Fusion in Lung Adenocarcinoma

Authors: Hui Li, Huicong Liu, Lisha Xiao, Huabin Gao, Huiting Wei, Anjia Han, Gengpeng Lin

Source: Current Oncology, Vol 31, Iss 11, Pp 6621-6631 (2024)

Subject Terms: KIF5B-NTRK1, lung adenocarcinoma, entrectinib, signaling pathways, case report, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.mdpi.com/1718-7729/31/11/489; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729

Access URL: https://doaj.org/article/cb8bb68df74c46bb9c120cdf1935b3ed

Targeting PYK2, entrectinib allays anterior subcapsular cataracts in mice by regulating TGFβ2 signaling pathway

Authors: Xuefei Ding, Xiaohe Li, Rui Fang, Peilin Yue, Yuxuan Jia, Enjie Li, Yayue Hu, Honggang Zhou, Xudong Song

Source: Molecular Medicine, Vol 30, Iss 1, Pp 1-15 (2024)

Subject Terms: Fibrotic cataract, EMT, Entrectinib, TGFβ2, PYK2, Therapeutics. Pharmacology, RM1-950, Biochemistry, QD415-436

File Description: electronic resource

Relation: https://doaj.org/toc/1528-3658

Access URL: https://doaj.org/article/d82b753279424a38a45ef2909c84d11f

Design and optimization of DPC-crosslinked HPβCD nanosponges for entrectinib oral delivery: formulation, characterization, and pharmacokinetic studies

Authors: Konda Sri Chaya Reddy, Darna Bhikshapathi

Source: Future Journal of Pharmaceutical Sciences, Vol 10, Iss 1, Pp 1-15 (2024)

Subject Terms: Box–Behnken design, Cross-linker, Hydroxypropyl-β-cyclodextrin, Solubility, Entrectinib, Diphenyl carbonate, Therapeutics. Pharmacology, RM1-950, Pharmacy and materia medica, RS1-441

File Description: electronic resource

Relation: https://doaj.org/toc/2314-7253

Access URL: https://doaj.org/article/0d79f4cbfa594c148f48c21167c5ca7c

Entrectinib-Induced Myocarditis and Acute Heart Failure Responding to Steroid Treatment: A Case Report

Authors: Mehraab N. Majeed, MBBCh, Subramanian Venkatesan, PhD, Dionysis Papadatos-Pastos, PhD, Tanya Ahmad, MD, Martin Forster, PhD, Polyvios Demetriades, MRCP, Daniel Johnathan Hughes, MRCP, Sarah Benafif, PhD, Siow Ming Lee, FRCP

Source: JTO Clinical and Research Reports, Vol 5, Iss 12, Pp 100746- (2024)

Subject Terms: Tyrosine kinase inhibitor, Entrectinib, Myocarditis, Acute heart failure, ROS-1, Case report, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364324001164; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/b022d0fdc0cb4dc2a6af6f341d77fb22

Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions

Authors: Desai, Ami V. ^a, Bagchi, Aditi ^b, Armstrong, Amy E. ^c, van Tilburg, Cornelis M. ^{d, e, f, g, h}, Basu, Ellen M. ⁱ, Robinson, Giles W. ^b, Wang, Huanmin ^j, Casanova, Michela ^k, André, Nicolas ^{l, m}, Campbell-Hewson, Quentin ⁿ, Wu, Yeming ^o, Cardenas, Alison ^p, Ci, Bo ^p, Ryklansky, Carolina ^{p, †}, Devlin, Clare E. ^q, Meneses-Lorente, Georgina ^q, Wulff, Jade ^p, Hutchinson, Katherine E. ^p, Gajjar, Amar ^b, Fox, Elizabeth ^{r, ⁎}

Source: In European Journal of Cancer 2 May 2025 220

ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models

Authors: Schmid, Sebastian ^{1, 8}, Russell, Zachary R. ^{1, 8}, Yamashita, Alex Shimura ², West, Madeline E. ¹, Parrish, Abigail G. ¹, Walker, Julia ¹, Rudoy, Dmytro ¹, Yan, James Z. ¹, Quist, David C. ¹, Gessesse, Betemariyam N. ¹, Alvinez, Neriah ¹, Hill, Kimberly D. ³, Anderson, Larry W. ³, Cimino, Patrick J. ⁴, Kumasaka, Debra K. ¹, Parchment, Ralph E. ², Holland, Eric C. ^{1, 5}, Szulzewsky, Frank ^{1, 6, 7, 9, ∗}

Source: In Cell Reports 22 October 2024 43(10)

Entrectinib Response to ROS1-Fusion-Positive Non-Small-Cell Lung Cancer That Progressed on Crizotinib with Leptomeningeal Metastasis: A Case Report

Authors: Hiromune Sawada, Yuri Taniguchi, Shin Iizuka, Toshiki Ikeda, Masaharu Aga, Yusuke Hamakawa, Kazuhito Miyazaki, Yuki Misumi, Yoko Agemi, Yukiko Nakamura, Koki Maeda, Tsuneo Shimokawa, Hiroaki Okamoto

Source: Case Reports in Oncology, Vol 16, Iss 1, Pp 1558-1567 (2023)

Subject Terms: entrectinib, ros1, crizotinib, leptomeningeal metastasis, non-small-cell lung cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://beta.karger.com/Article/FullText/534549; https://doaj.org/toc/1662-6575

Access URL: https://doaj.org/article/97ef3a05d08549e587029f538dbb0f84

Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report

Authors: Shaheenah Dawood, Zulfaqqar Jaffar Ali

Source: Case Reports in Oncology, Vol 16, Iss 1, Pp 1451-1459 (2023)

Subject Terms: case report, metastatic melanoma, entrectinib, ntrk3 gene fusion, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://beta.karger.com/Article/FullText/534475; https://doaj.org/toc/1662-6575

Access URL: https://doaj.org/article/d6ef7913c3d84b218d58bb78d3ec3999

Refractory response to entrectinib for ROS‐1 rearranged NSCLC with concurrent de novo TP53 mutation showing good response to CNS lesion, but poor duration of response: A case report

Authors: Kentaro Ito, Miho Nishio, Kentaro Fujiwara, Yoichi Nishii, Kengo Ushiro, Hiroki Yasui, Osamu Hataji

Source: Thoracic Cancer, Vol 14, Iss 25, Pp 2622-2626 (2023)

Subject Terms: brain metastasis, entrectinib, ROS‐1 fusion, TP53 mutation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1759-7706; https://doaj.org/toc/1759-7714

Access URL: https://doaj.org/article/c9e35c4ba19f4a5ab1b76c5ed0c10dfb

Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report

Authors: Dan Li, Yue Zhu, Jincheng Song, Dafu Yang, Saiqiong Cui, Xin Liu, Le Wang, Jiangyan Zhang, Evenki Pan, Zhaoxia Dai

Source: Frontiers in Oncology, Vol 14 (2024)

Subject Terms: ALK rearrangement, brigatinib, entrectinib, resistance mutations, ETV6-NTRK3, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1339511/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/86d94ff29ae34a21991f4c647c2ab4bb

MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements

Authors: Yohei Takumi, Sachiko Arai, Chiaki Suzuki, Koji Fukuda, Akihiro Nishiyama, Shinji Takeuchi, Hiroki Sato, Kunio Matsumoto, Kenji Sugio, Seiji Yano

Source: Cancer Medicine, Vol 12, Iss 5, Pp 5809-5820 (2023)

Subject Terms: entrectinib, HGF, MET, NTRK, ROS1, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/85ba3ce3a3324891940d24db346f1dfd

From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis

Authors: Zhiwei Cui, Zhen Zhai, De Xie, Lihui Wang, Feiyan Cheng, Siyu Lou, Fan Zou, Rumeng Pan, Shixue Chang, Haoyan Yao, Jing She, Yidan Zhang, Xinyuan Yang

Source: Frontiers in Pharmacology, Vol 15 (2024)

Subject Terms: NTRK, gene fusion, entrectinib, larotrectinib, FAERS, adverse drug event, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2024.1329409/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/f3a6c4fba82a49028ed33818ada829d9

A case of hepatic dysfunction from crizotinib followed by treatment with entrectinib

Authors: Takahito Mizuno, Satoshi Hagimoto, Takumi Umemura, Mariko Higashikawa, Takamasa Sakai, Kouichi Tanabe, Fumiko Ohtsu, Tetsuya Yamada, Tomoki Kimura

Source: Current Problems in Cancer: Case Reports, Vol 12, Iss , Pp 100262- (2023)

Subject Terms: Small molecule tyrosine kinase inhibitor, Crizotinib, Entrectinib, Hepatic dysfunction, Increased creatinine phosphokinase, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666621923000467; https://doaj.org/toc/2666-6219

Access URL: https://doaj.org/article/86ac38627cd94325923d9641bcce7955

Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report

Authors: Elio Gregory Pizzutilo, MD, Alberto Giuseppe Agostara, MD, Laura Roazzi, MD, Rebecca Romanò, MD, Valentina Motta, PhD, Calogero Lauricella, PhD, Giovanna Marrapese, PhD, Giulio Cerea, MD, Diego Signorelli, MD, PhD, Silvio Marco Veronese, PhD, Laura Giuseppina Giannetta, MD, Andrea Sartore-Bianchi, MD, Salvatore Siena, MD

Source: JTO Clinical and Research Reports, Vol 4, Iss 11, Pp 100555- (2023)

Subject Terms: Case report, Entrectinib, Repotrectinib, Resistance, ROS1 F2004V, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S266636432300098X; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/d61ce692b70b43e5b3a2d9ee7b951f11

Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report

Authors: Inês Damásio, Joana Simões-Pereira, Sara Donato, Mariana Horta, Branca Maria Cavaco, Miguel Rito, Pedro Gomes, Valeriano Leite

Source: European Thyroid Journal, Vol 12, Iss 1, Pp 1-6 (2023)

Subject Terms: anaplastic thyroid carcinoma, entrectinib, neoadjuvancy, precision medicine, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

File Description: electronic resource

Relation: https://etj.bioscientifica.com/view/journals/etj/12/1/ETJ-22-0179.xml; https://doaj.org/toc/2235-0802

Access URL: https://doaj.org/article/ce4f4c55ac8a40e1926b81153d0bc38f

MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC

Authors: Logan C. Tyler, Anh T. Le, Nan Chen, Hala Nijmeh, Liming Bao, Timothy R. Wilson, David Chen, Brian Simmons, Kristen M. Turner, Dean Perusse, Shailaja Kasibhatla, Jason Christiansen, Arkadiusz Z. Dudek, Robert C. Doebele

Source: Thoracic Cancer, Vol 13, Iss 21, Pp 3032-3041 (2022)

Subject Terms: drug resistance, entrectinib, MET, NSCLC, ROS1, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1759-7706; https://doaj.org/toc/1759-7714

Access URL: https://doaj.org/article/69b9447303ff45faa281860090224996

NTRK Somatic Fusions and Tumor Agnostic Treatment in Pediatric Cancers

Authors: Emel Ünal, Sonay İncesoy Özdemir, Ayça Yağmur Şimşek

Source: Journal of Contemporary Medicine, Vol 12, Iss 6, Pp 1019-1024 (2022)

Subject Terms: ntrk füzyonu, tümör agnostik tedavi, hassas tıp, larotrectinib, entrectinib, ntrk fussion, tumor agnostic treatment, precision medicine, Medicine

File Description: electronic resource

Relation: https://dergipark.org.tr/tr/download/article-file/2414338; https://doaj.org/toc/2667-7180

Access URL: https://doaj.org/article/2c2440fcc5bd471885750cdac3cb780e

Anticancer Drugs 2021

Contributors: Meegan, Mary J, O’Boyle, Niamh M

Subject Terms: thymidylate synthase, cytotoxicity, 1,2,3-triazole, 1,3,4-oxadiazole, 5-fluoruracil, pemetrexed, docking, 3,4′-bis-guanidino, 3-amino-4′-guanidino, diphenyl ether, phenyl pyridyl ether, intramolecular hydrogen bond, cancer cell viability, HL-60, BRAF, apoptosis, thieno[2,3-d][1,2,3]triazine, acetamide, H1299, HER2, EGFR, Bcl-2 inhibitors, Indole-based analogues, benzimidazole, MTT cytotoxic assay, cell cycle analysis, DNA fragmentation, ELISA, solid/lipid nanoparticles, phenstatin, letrozole, tubulin polymerisation inhibitor, aromatase inhibitor, breast cancer, hybrid molecule, dual-targeting molecule, designed multiple ligand, NaMSA, cyclophosphamide, histopathology, testis, urinary bladder, anticancer agents, enantioselective synthesis, gastric adenocarcinoma, tryptophanol, concentration-guided dosing, model informed dosing, physiologically based pharmacokinetics, sorafenib, tyrosil-DNA-phosphodiesterase 1, adamantane, resin acid, TDP1, cytotoxic agents, apoptosis induction, HT-29 cells, MDA-MB-231 cells, mechanism prediction, STAT inhibitors, miR-21, hydrazide derivatives, nitrogen scaffolds, mitoxantrone, cardiotoxicity, inflammation, oxidative stress, age, cumulative dose, Trk, NTRK, tissue-agnostic, larotrectinib, entrectinib, Trk fusion, protein kinase inhibitors, USFDA, cancer, patent review, generic product, doxazosin, MD simulations, combretastatin A-4, cytotoxic activity, hybrid compounds, indazole, mucin, MUC1, MUC16, immunotherapy, cancer vaccine, CAR (chimeric antigen receptor), ADC (antibody-drug conjugate), thiourea, interleukin-6, trypan blue assay, chalcones, exportin-1, covalent binding, CovDock, anticancer activity, xanthone, in vitro, in vivo, isolation, synthesis, heterocyclic compound, benzenesulfonamides, imidazoles, alkylated, colony formation, tumor spheroids, HDAC inhibitors, chalcone, dual inhibitors, carvedilol, kidney, toxicity, 7-deaza-4′-thioadenosine derivatives, multi-kinase inhibitor, anticancer, nucleoside, Imiquimod, drug efflux, multidrug resistance, Toll-Like Receptor, Research and information: general, Chemistry

File Description: application/octet-stream

Access URL: https://directory.doabooks.org/handle/20.500.12854/84569
https://mdpi.com/books/pdfview/book/5551

Entrectinib‐induced syndrome of inappropriate antidiuretic hormone secretion in a patient with ROS1‐rearranged non‐small cell lung cancer

Authors: Chiaki Kato, Muneyuki Sekiya, Ryo Sekiguchi, Akira Yamasaki, Takahiro Yoshizawa, Kazutoshi Isobe, Naobumi Tochigi, Kazutoshi Shibuya, Kazuma Kishi

Source: Respirology Case Reports, Vol 11, Iss 10, Pp n/a-n/a (2023)

Subject Terms: Entrectinib, hyponatremia, non‐small cell lung cancer, ROS‐1, syndrome of inappropriate antidiuretic hormone secretion, Diseases of the respiratory system, RC705-779

File Description: electronic resource

Relation: https://doaj.org/toc/2051-3380

Access URL: https://doaj.org/article/07c6a49c57584e118620bc982b62f098